Poland Neurology Clinical Trials Market Report 2022 to 2030

Poland Neurology Clinical Trials Market Analysis

$ 3999

The Poland Neurology Clinical Trials market is projected to grow from $30.3 Mn in 2022 to $48.2 Mn by 2030, registering a CAGR of 5.95% during the forecast period of 2022 - 2030. The market will be driven by a skilled workforce, a supportive regulatory framework, and a relatively low cost of conducting research. The market is segmented by phase, by study design & by indication. Some of the major players include Biogen Inc., Pfizer Inc. & Novartis AG.

ID: IN10PLCT005 CATEGORY: Clinical Trials GEOGRAPHY: Poland AUTHOR: Vidhi Upadhyay

Buy Now

Poland Neurology Clinical Trials Market Executive Summary

The Poland Neurology Clinical Trials market is projected to grow from $30.3 Mn in 2022 to $48.2 Mn by 2030, registering a CAGR of 5.95% during the forecast period of 2022 - 2030. Poland is situated in Central Europe, with a population of 37.9 million people, and is the European Union's fifth-most populated member state. Poland is one of the major clinical trial markets in CEE, accounting for over 20% of all clinical studies conducted. According to the most recent WHO statistics, Alzheimer's and Dementia fatalities in Poland reached 3,701 in 2020, accounting for 1.04% of all deaths. In Poland, around 90,000 strokes occur each year, with 85% of them being ischemic.

Clinical trials are an essential element in healthcare research since they are used to evaluate the quality and safety of new drugs, medical equipment, or treatments. Clinical trials are conducted to determine that innovative therapies or drugs are safe, effective, and appropriate for use in patient care. Neurology clinical trials, in particular, focus on treatments for neurological ailments such as Alzheimer's disease, multiple sclerosis, Parkinson's disease, stroke, and others. Poland is a developing nation in clinical trials and has been actively participating in neurology clinical trials. Throughout the last decade, the number of clinical trials undertaken in Poland has steadily increased. While there are obstacles to the expansion of neurology clinical trials in Poland, the nation has a trained workforce, a supportive regulatory environment, and a relatively cheap cost of doing research, all of which are big factors for the field's continued expansion.

Poland Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

The trained workforce in Poland is one of the key drivers of neurology clinical trials. Poland offers a huge pool of highly skilled medical experts, such as neurologists and clinical researchers, who can perform clinical trials professionally and efficiently. Poland has a well-developed clinical trial regulatory system that is in line with the EU Clinical Trials Regulation and corresponds to worldwide clinical research standards. Moreover, Poland has cheaper expenses by 30% on average than the US, owing to efficiency in patient recruiting and lower wages and fees and has launched various measures to stimulate cooperation between business and academics, which has aided in the expansion of clinical trial operations in the area of neurology.

Market Restraints

The small patient population is one of the major impediments to the expansion of neurology clinical trials in Poland. Poland has a smaller population than many other nations, which might restrict the number of people who are eligible for clinical studies. More financing for a clinical study is required in Poland since many hospitals and research organisations have low financial resources. This may lead to a scarcity of competent employees and insufficient infrastructure, limiting the expansion of clinical trials. Other nations in the area that are investing in clinical research, such as the Czech Republic and Hungary, compete with Poland.

Competitive Landscape

Key Players

Biogen Inc.
Pfizer Inc.
Novartis AG
Sanofi S.A.
Merck & Co.
AbbVie
Roche Holding AG
AstraZeneca plc
Eli Lilly and Company
GlaxoSmithKline

Healthcare Policies and Regulatory Landscape

Clinical trials might be funded privately or publicly. The product producer frequently funds commercial clinical studies (pharmaceutical company). The Medical Research Agency, formed in 2019, is the governmental entity in charge of supporting non-commercial clinical studies, such as those done by scientific organisations, universities, and so on. Before a medicine or device study may begin in Poland, the Regulatory Agency/Competent Authority (RA) and the Ethics Committee (EC) must both approve it.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.